RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $3.00 Consensus Target Price from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has earned an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $3.00.

A number of research analysts recently weighed in on the company. HC Wainwright upgraded RAPT Therapeutics to a "strong-buy" rating and set a $6.00 target price on the stock in a report on Thursday, May 22nd. Wall Street Zen raised RAPT Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, UBS Group decreased their target price on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd.

RAPT Therapeutics Stock Up 3.2%

Shares of RAPT traded up $0.03 during mid-day trading on Tuesday, hitting $1.02. The company had a trading volume of 409,286 shares, compared to its average volume of 1,281,617. RAPT Therapeutics has a 1-year low of $0.71 and a 1-year high of $4.23. The business's 50-day simple moving average is $0.93 and its 200-day simple moving average is $1.12. The stock has a market cap of $134.93 million, a PE ratio of -0.37 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.23. On average, sell-side analysts expect that RAPT Therapeutics will post -2.14 earnings per share for the current year.

Institutional Investors Weigh In On RAPT Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. TCG Crossover Management LLC acquired a new position in RAPT Therapeutics during the 4th quarter worth approximately $19,751,000. Orbimed Advisors LLC purchased a new stake in shares of RAPT Therapeutics during the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC purchased a new stake in shares of RAPT Therapeutics during the fourth quarter valued at approximately $19,750,000. RTW Investments LP acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth $18,587,000. Finally, BVF Inc. IL purchased a new position in shares of RAPT Therapeutics in the fourth quarter valued at $14,595,000. Hedge funds and other institutional investors own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.